Abstract
The results of a phase II clinical trial of hexamethylmelamine in 23 patients with small cell carcinoma of the lung are presented. The overall response rate was 43%. The median survival time was 5.5 mth and the mean survival time was 8.4 mth. The most frequent side effects were nausea and vomiting; the hematopoietic toxicity was rather mild and transient. Because of relatively mild side effects, hexamethylmelamine should be further evaluated for treatment of small cell carcinoma in combination with other chemotherapeutic agents or with radiation therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 371-374 |
| Number of pages | 4 |
| Journal | CANCER CHEMOTHER.REP. |
| Volume | 58 |
| Issue number | 3 |
| State | Published - Dec 1 1974 |
ASJC Scopus subject areas
- General Medicine